Gut health is largely defined by the balance between eubiosis and dysbiosis. Eubiosis reflects a stable microbial ecosystem dominated by beneficial species, while dysbiosis involves overgrowth of pathogenic organisms, leading to inflammation, impaired barrier function, and conditions such as diarrhea, inflammatory bowel disease, and metabolic disorders.^[1] Probiotics play a key role in restoring this balance by maintaining gut flora, inhibiting pathogens, and improving treatment tolerability in gastrointestinal disorders.^[2] Saccharomyces boulardii CNCM I-745 is a distinct yeast probiotic with superior resistance to gastric stress, antibiotics, and environmental factors, enhancing its clinical effectiveness. Its unique properties support microbiota restoration, help prevent antibiotic-associated diarrhea, and promote gastrointestinal health with rapid clinical benefits.^[3]